PHGDH and non-small cell lung carcinoma: Non-small cell lung cancer (NSCLC) and melanoma cancer models treated with vemurafenib activated serine/glycine synthesis as a mechanism of acquired resistance to targeted therapy, and the silencing of PHGDH reversed resistance to therapy [43].